# Efficacy of Interleukin-2 in Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct05821686/  
OnCo record `nct05821686` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in triple-negative breast cancer, run by Nova Scotia Health Authority, not yet recruiting.

## Summary

Efficacy of Interleukin-2 in Triple Negative Breast Cancer is a phase 1/2, interventional study registered as NCT05821686 by Nova Scotia Health Authority, with a registry enrolment figure of 10 participants, started 2026-01-02 and due to reach its primary completion in 2028-04. Interventions recorded: Human Interleukin-2 (IL-2) (Proleukin). Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Women with biopsy proven TNBC who are not scheduled to receive neoadjuvant chemotherapy". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05821686
- Phase: 1/2
- Setting: Efficacy of Intralesional IL-2 for Resectable Triple Negative Breast Cancer
- Sponsor: Nova Scotia Health Authority
- Enrolled: 10

## Sources

- ClinicalTrials.gov NCT05821686: https://clinicaltrials.gov/study/NCT05821686

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05821686.json